The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1α,25- dihydroxyvitamin D2 as therapeutic agents for prostate cancer

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 901-908

  Chen, Tai C ^a,d   Schwartz, Gary G ^b   Burnstein, Kerry L ^c   Lokeshwar, Bal L ^c   Holick, Michael F ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; HORMONE PRECURSOR;

ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSACTIVATION;

NON-PROGRAMMATIC;

CALCIFEDIOL; CELL COUNT; CELL DIVISION; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RECOMBINANT FUSION PROTEINS; THYMIDINE; TRANS-ACTIVATION (GENETICS); TRITIUM; TUMOR CELLS, CULTURED;

EID: 0034061507     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Kirby, K. S. Recent advances in the medical management of prostate cancer. Br. J. Clin. Pract., 50: 88-93, 1996.
3. Campbell, M. J., and Koeffler, H. P. Toward the intervention of cancer with vitamin D compounds. J. Natl. Cancer Inst., 89: 182-183, 1997.
4. 3. Cancer Res., 52: 515-520, 1992.
5. 3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952-1960, 1993.
6. Schwartz, G. G., Oeler, T. A., Uskokovic, M. R., and Bahnson, R. R. Human prostate cancer cell lines: inhibition of proliferation by vitamin D analogs. Anticancer Res., 14: 1077-1081, 1994.
7. 3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
8. Schwartz, G. G., Wang, M-H., Zhang, M., Singh, R. J., and Siegal, G. P. 1α,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomark. Prev., 6: 727-732, 1997.
9. Lokeshwar, B. L., Schwartz, G. G., Selzer, M. G., Burnstein, K. L., Zhuang, S-H., Block, N. L., and Binderup, L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol. Biomark. Prev., 8: 241-248, 1999.
10. Osborn, J. L., Schwartz, G. G., Bahnson, R., Smith, D. C., and Trump, D. L. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol., 1: 195-198, 1995.
11. 3 (calcitriol). J. Urol., 159: 2035-2040, 1998.
12. 3. Cancer Epidemiol. Biomark. Prev., 7: 391-395, 1998.
13. 3-1-α-hydroxylase in cultured human prostatic cells. Bone, 23 (Suppl.): S262, 1998.
14. Breslau, N. A., and Zerwekh, J. E. Pharmacology of vitamin D preparations. In: D. Feldman, F. H. Glorieux, and J. W. Pike (eds.), Vitamin D, pp. 607-618. New York: Academic Press, 1997.
15. 2. Am. J. Kidney Dis., 32 (Suppl. 2): S48-S54, 1998.
16. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J. Am. Soc. Nephrol., 9: 1427-1432, 1998.
17. Lokeshwar, B. L., Selzer, M. B., Block, N. L., and Gunja-Smith, Z. Secretion of matrix metalloproteinases and their inhibitors (TIMPs) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res., 51: 4493-4498, 1993.
18. 3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. J. Investig. Dermatol., 104: 113-117, 1995.
19. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J. Investig. Dermatol., 86: 709-714, 1986.
20. Zhuang, S-H., Schwartz, G. G., Cameron, D., and Burnstein, K. L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol. Cell. Endocrinol., 126: 83-90, 1997.
21. 1 accumulation. Endocrinology, 139: 1197-1207, 1998.
22. Gorman, C. M., Moffat, L. F., and Howard, B. H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol., 2: 1044-1051, 1982.
23. Schwartz, G. G., and Hulka, B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res., 10: 1307-1311, 1990.
24. Schwartz, G. G. Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology, 11:244-254, 1992.
25. Hanchette, C. L., and Schwartz, G. G. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer (Phila.), 70: 2861-2869, 1992.
26. kip1 and E-cadherin. J. Mol. Endocrinol., 19: 15-27, 1997.
27. 3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast, and myeloid leukemia cell lines. Anticancer Res., 19: 1689-1698, 1999.
28. 3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res., 59: 4023-4029, 1999.
29. Schwartz, G. G., Hill, C. C., Oeler, T. A., Becich, M. J., and Bahnson, R. R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D, and prostate cancer cell proliferation in vivo. Urology, 46: 365-369, 1995.
30. Binderup, L., Binderup, E., and Gotfredsen, W. O. Development of new vitamin D analogs. In: D. Feldman, F. H. Glorieux, and J. W. Pike (eds.), Vitamin D, pp. 1027-1043. New York: Academic Press, 1997.
31. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin. Cancer Res., 5: 695-703, 1999.
32. 3 analogue and anti-activator protein 1 retinoid. Br. J. Cancer, 79: 101-107, 1999.
33. 3. J. Clin. Investig., 58: 61-70, 1976.
34. Jones, G. Metabolism and catabolism of vitamin D, its metabolites, and clinically relevant analogs. In: M. F. Holick (ed.), Vitamin D: Molecular Biology, Physiology, and Clinical Applications, pp. 57-84. Totowa, New Jersey: Humana Press, 1999.
35. Byne, P. M., Freaney, R., and McKenna, M. J. Vitamin D supplementation of the elderly: review of safety and effectiveness of various regimens. Calcif. Tissue Int., 56: 518-520, 1995.
36. Barger-lux, M. J., Heaney, R. P., Dowell, S., Chen, T. C., and Holick, M. F. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporosis Int., 8: 222-230, 1998.
37. Dusso, A., Brown, A., and Slatopolsky, E. Extrarenal production of calcitriol. Semin. Nephrol., 14: 144-155, 1994.
38. Shipley, G. D., and Pittelkow, M. R. Control of growth and differentiation in vitro of human keratinocytes cultured in serum-free medium. Arch. Dermatol., 123: 1541a-1544a, 1987.
39. 3. Endocrinology, 136: 20-26, 1995.